Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HLA-A*03:01 (Tetramer) protein (KRAS)

Origin: Human Host: HEK-293 Cells Recombinant > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Catalog No. ABIN7454302
  • Target
    HLA-A*03:01
    Protein Type
    Recombinant
    Protein Characteristics
    Tetramer
    Origin
    Human
    Source
    • 10
    • 1
    HEK-293 Cells
    Purification tag / Conjugate
    KRAS
    Purpose
    Human HLA-A*03:01 & B2M & KRAS WT (VVVGAGGVGK) Tetramer Protein
    Sequence
    Gly25-Thr305 (HLA-A*03:01) & Ile21-Met119 (B2M) and VVVGAGGVGK peptide
    Specificity
    Uni-Prot: NP_002107.3 (HLA-A*03:01), P61769 (B2M), VVVGAGGVGK
    Characteristics
    Recombinant Human KRAS WT(HLA-A*03:01) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide.
    Purity
    > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
    Sterility
    0.22 μm filtered
    Endotoxin Level
    Less than 1EU per μg by the LAL method.
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
    Buffer
    Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
    Storage
    -20 °C,-80 °C
    Storage Comment
    -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Expiry Date
    12 months
  • Target
    HLA-A*03:01
    Background
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    Molecular Weight
    258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
    NCBI Accession
    NP_002107
You are here:
Support